Cellyan Biotechnology
Cross-border OTC pharmaceutical fulfillment and distribution for Mainland Chinese e-commerce.
Something off on this page? Send us feedback.
Profile
Provides regulated cross-border supply-chain services and OTC pharmaceutical procurement and distribution for business customers serving Mainland Chinese e-commerce demand. Hong Kong subsidiaries earn service fees for fulfillment and sell products to merchants and pharmaceutical distributors under a Cayman holding company.
Provides regulated cross-border supply-chain services and procurement and distribution of overseas OTC pharmaceuticals for merchants and logistics partners serving Mainland Chinese e-commerce customers. Its Hong Kong operations review products, handle Department of Health registrations and import/export documentation, warehouse and package goods, coordinate customs clearance, and arrange delivery handoffs.
Earns service fees for order processing, warehousing, customs clearance and value-added work; separately sources OTC products, arranges their import, and sells them to platform merchants and pharmaceutical distributors. A proprietary ERP integrates order processing with warehouse-management software and supports batch packing.
Operations are concentrated in Hong Kong, with demand tied mainly to Mainland Chinese cross-border e-commerce. Licenses, eligible-product registration, suppliers, outsourced customs and delivery services, contracted labor, and relationships with logistics partners and merchants underpin execution.
Company facts
Categories
Key statistics
Year to date −57.1% · Average volume (30d) 887.3K
Analysts
No analyst consensus on record.
Earnings
Not reported.
Financial highlights
| 6 quarters | Q2 FY24 | Q4 FY24 | Q2 FY25 | Q4 FY25 | Q2 FY26 | Q4 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $7.0M | $9.7M | $11.1M | $9.2M | $7.1M | $6.3M | |
| Gross profit | $1.3M | $2.2M | $1.9M | $509.6K | $930.8K | $455.5K | |
| Operating income | $308.8K | $1.3M | $1.0M | −$895.0K | $234.3K | −$1.2M | |
| Net income | $249.0K | $1.1M | $828.6K | −$855.6K | $153.7K | −$1.3M | |
| Diluted EPS | $0.04 | $0.11 | $0.08 | −$0.08 | $0.01 | −$0.04 | |
| Gross margin | 19.1% | 23.0% | 17.2% | 5.5% | 13.0% | 7.2% | |
| Operating margin | 4.4% | 13.4% | 9.3% | -9.7% | 3.3% | -19.5% |
Revenue by product · FY26
Balance sheet, Sep 30, 2025Cash & short-term investments $2.5M · Total debt $2.3M · Total assets $9.6M · Shareholders' equity $5.1M
Dividends
No dividends on record.
Ownership
Shares outstanding 10.98M · Float 3.21M · 29.2% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| TUTU Business Services Limited | 7.15M | 65.00% | 13D | Nov 12, 2025 |
| Lap Sun Wong | 6.24M | 56.77% | 13G | Jun 3, 2025 |
| Atlantic Health Century International Group | 617.9K | 5.62% | 13G | Jun 5, 2025 |
| Pacific Health Century International Group | 617.9K | 5.62% | 13G | Jun 5, 2025 |
| Stonex Group Inc. | 39.4K | 0.36% | 13F | May 14, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
View detailsPeers
Not reported.